About Recombine
Recombine is a company based in New York (United States) founded in 2011 was acquired by CooperSurgical in May 2016. Recombine has raised $12.07 million across 3 funding rounds from investors including FirstMark, Vast Ventures and Zach Weinberg. Recombine offers products and services including Paragard, Endosee Advance System, and RUMI II. Recombine operates in a competitive market with competitors including Natera, Invitae, Helix, Myriad Genetics and BillionToOne, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Coopersurgical, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.07 M (USD)
in 3 rounds
-
Latest Funding Round
$8.44 M (USD), Series B
Jul 06, 2016
-
Investors
FirstMark
& 5 more
-
Employee Count
Not available
-
Acquired by
CooperSurgical
(May 25, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Recombine
Recombine offers a comprehensive portfolio of products and services, including Paragard, Endosee Advance System, and RUMI II.
Intrauterine device for long-term birth control.
Device for hysteroscopic visualization and diagnostics.
Surgical manipulator for uterine procedures.
Funding Insights of Recombine
Recombine has successfully raised a total of $12.07M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $8.44 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Recombine
Recombine has secured backing from 6 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include FirstMark, Vast Ventures and Zach Weinberg.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused venture capital firm
|
Locked | Locked | Locked | |
|
Early-stage venture capital is invested in tech startups across sectors.
|
Locked | Locked | Locked | |
|
Offers medical devices for fertility, contraception, and women's health care globally.
|
Locked | Locked | Locked |
Investor details for Recombine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Recombine
Investment portfolio details for Recombine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Recombine
Detailed financials for Recombine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Recombine Comparisons
Peer comparison for Recombine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Recombine
Recombine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, Invitae, Helix, Myriad Genetics and BillionToOne, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| Locked | Locked | Locked |
Genomic database for clinical research is provided.
|
|
| Locked | Locked | Locked |
Molecular diagnostics and personalized medicine for cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Genomic testing services are provided clinically and directly to consumers.
|
Detailed competitors of Recombine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Recombine
Complete news archive for Recombine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Recombine
Recombine was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Recombine is headquartered in New York, United States. It is registered at New York, New York, United States.
Recombine is a funded company, having raised a total of $12.07M across 3 funding rounds to date.
Recombine was founded in 2011 in New York, United States, and operates in the genetic testing sector. Clinical services are offered, including CarrierMap for comprehensive carrier screening and ChromoMap for non-invasive prenatal chromosome analysis using maternal blood. Sample collection and genetic counseling are also managed to support testing processes. Operations focus on reducing risks associated with invasive procedures.
Recombine's top competitors include Helix, Natera and Fulgent Genetics.
Recombine offers Paragard, Endosee Advance System, and RUMI II.
Recombine has 6 investors. Key investors include FirstMark, Vast Ventures, Zach Weinberg, Nat Turner, and Vivek Garipalli.